David Nutt
David Nutt | |
|---|---|
Professor David Nutt, February 2020 | |
| Born | 16 April 1951 Bristol, England, United Kingdom |
| Nationality | British |
| Education | Bristol Grammar School |
| Alma mater | Downing College, Cambridge |
| Known for | Founding Drug Science Controversial removal from the Advisory Council on the Misuse of Drugs Performing the first MRI of a human brain under the influence of LSD Ecstasy controversy |
| Scientific career | |
| Institutions | Drug Science Imperial College London University of Cambridge University of Oxford University of Bristol Guy's Hospital Advisory Council on the Misuse of Drugs (ACMD) Independent Scientific Committee on Drugs (ISCD) The European Brain Council |
| Thesis | The effect of convulsions and drugs on seizure susceptibility in rats (1982) |
| Website | drugscience |
David John Nutt (born 16 April 1951) is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs. In 2019 he co-founded the company GABAlabs and its subsidiary SENTIA Spirits which research and market alternatives to alcohol. Until 2009, he was a professor at the University of Bristol heading their Psychopharmacology Unit. Since then he has been the Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Nutt was a member of the Committee on Safety of Medicines, and was President of the European College of Neuropsychopharmacology.